A citation-based method for searching scientific literature

Bhumsuk Keam, Seock-Ah Im, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, In Ae Park, Dong-Young Noh, Dae Seog Heo, Yung-Jue Bang. Breast Cancer Res 2011
Times Cited: 148

List of co-cited articles
517 articles co-cited >1

Times Cited
  Times     Co-cited

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007

Ki67 in breast cancer: prognostic and predictive potential.
Rinat Yerushalmi, Ryan Woods, Peter M Ravdin, Malcolm M Hayes, Karen A Gelmon. Lancet Oncol 2010

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Mitch Dowsett, Torsten O Nielsen, Roger A'Hern, John Bartlett, R Charles Coombes, Jack Cuzick, Matthew Ellis, N Lynn Henry, Judith C Hugh, Tracy Lively,[...]. J Natl Cancer Inst 2011

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri Davies, Philip S Bernard, Joel S Parker,[...]. J Natl Cancer Inst 2009

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.
Mohammed A Aleskandarany, Andrew R Green, Ahmed A Benhasouna, Fabricio F Barros, Keith Neal, Jorge S Reis-Filho, Ian O Ellis, Emad A Rakha. Breast Cancer Res 2012

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014

Proliferation marker Ki-67 in early breast cancer.
Ander Urruticoechea, Ian E Smith, Mitch Dowsett. J Clin Oncol 2005

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Maggie C U Cheang, David Voduc, Chris Bajdik, Samuel Leung, Steven McKinney, Stephen K Chia, Charles M Perou, Torsten O Nielsen. Clin Cancer Res 2008

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.
Elisabetta Munzone, E Botteri, A Sciandivasci, G Curigliano, F Nolè, M Mastropasqua, N Rotmensz, M Colleoni, A Esposito, L Adamoli,[...]. Breast Cancer Res Treat 2012

Prognostic markers in triple-negative breast cancer.
Emad A Rakha, Maysa E El-Sayed, Andrew R Green, Andrew H S Lee, John F Robertson, Ian O Ellis. Cancer 2007

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
Peter A Fasching, Katharina Heusinger, Lothar Haeberle, Melitta Niklos, Alexander Hein, Christian M Bayer, Claudia Rauh, Ruediger Schulz-Wendtland, Mayada R Bani, Michael Schrauder,[...]. BMC Cancer 2011

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Torsten O Nielsen, Forrest D Hsu, Kristin Jensen, Maggie Cheang, Gamze Karaca, Zhiyuan Hu, Tina Hernandez-Boussard, Chad Livasy, Dave Cowan, Lynn Dressler,[...]. Clin Cancer Res 2004

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013

A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.
V Guarneri, F Piacentini, G Ficarra, A Frassoldati, R D'Amico, S Giovannelli, A Maiorana, G Jovic, P Conte. Ann Oncol 2009

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
E de Azambuja, F Cardoso, G de Castro, M Colozza, M S Mano, V Durbecq, C Sotiriou, D Larsimont, M J Piccart-Gebhart, M Paesmans. Br J Cancer 2007

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
C Denkert, S Loibl, B M Müller, H Eidtmann, W D Schmitt, W Eiermann, B Gerber, H Tesch, J Hilfrich, J Huober,[...]. Ann Oncol 2013

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, Ingrid A Mayer, Melinda E Sanders, Luca Gianni. Nat Rev Clin Oncol 2016

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
Keith N Ogston, Iain D Miller, Simon Payne, Andrew W Hutcheon, Tarun K Sarkar, Ian Smith, A Schofield, Steven D Heys. Breast 2003

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L Graham, Charles M Perou. Clin Cancer Res 2007

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, Karen L Hagerty, D Craig Allred, Richard J Cote, Mitchell Dowsett, Patrick L Fitzgibbons, Wedad M Hanna, Amy Langer,[...]. J Clin Oncol 2007

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Hiroko Masuda, Keith A Baggerly, Ying Wang, Ya Zhang, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam, Vicente Valero, Brian D Lehmann, Jennifer A Pietenpol, Gabriel N Hortobagyi,[...]. Clin Cancer Res 2013

Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry.
E C Inwald, M Klinkhammer-Schalke, F Hofstädter, F Zeman, M Koller, M Gerstenhauer, O Ortmann. Breast Cancer Res Treat 2013

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Qi-Xing Tan, Qing-Hong Qin, Wei-Ping Yang, Qin-Guo Mo, Chang-Yuan Wei. Int J Clin Exp Pathol 2014

Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients.
Hiroko Masuda, Norikazu Masuda, Yoshinori Kodama, Masami Ogawa, Michiko Karita, Jun Yamamura, Kazunori Tsukuda, Hiroyoshi Doihara, Shinichiro Miyoshi, Masayuki Mano,[...]. Cancer Chemother Pharmacol 2011

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.
Elisabeth Luporsi, Fabrice André, Frédérique Spyratos, Pierre-Marie Martin, Jocelyne Jacquemier, Frédérique Penault-Llorca, Nicole Tubiana-Mathieu, Brigitte Sigal-Zafrani, Laurent Arnould, Anne Gompel,[...]. Breast Cancer Res Treat 2012

An international Ki67 reproducibility study.
Mei-Yin C Polley, Samuel C Y Leung, Lisa M McShane, Dongxia Gao, Judith C Hugh, Mauro G Mastropasqua, Giuseppe Viale, Lila A Zabaglo, Frédérique Penault-Llorca, John M S Bartlett,[...]. J Natl Cancer Inst 2013

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.
Robin L Jones, Janine Salter, Roger A'Hern, Ash Nerurkar, Marina Parton, Jorge S Reis-Filho, Ian E Smith, Mitchell Dowsett. Breast Cancer Res Treat 2009

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, Chad A Livasy, Lynn G Dressler, David Cowan, Kathleen Conway, Gamze Karaca, Melissa A Troester, Chiu Kit Tse, Sharon Edmiston,[...]. JAMA 2006

Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates.
Minoru Miyashita, Takanori Ishida, Kazuyuki Ishida, Kentaro Tamaki, Masakazu Amari, Mika Watanabe, Noriaki Ohuchi, Hironobu Sasano. Virchows Arch 2011

Hydrogen sulfide in cancer: Friend or foe?
Dongdong Wu, Weirong Si, Mingjie Wang, Shuangyu Lv, Ailing Ji, Yanzhang Li. Nitric Oxide 2015

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H M Kuerer, L A Newman, T L Smith, F C Ames, K K Hunt, K Dhingra, R L Theriault, G Singh, S M Binkley, N Sneige,[...]. J Clin Oncol 1999

Ki67--no evidence for its use in node-positive breast cancer.
Fabrice Andre, Monica Arnedos, Aicha Goubar, Amal Ghouadni, Suzette Delaloge. Nat Rev Clin Oncol 2015

Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas.
Ivana Mrklić, Vesna Ćapkun, Zenon Pogorelić, Snježana Tomić. Pathol Res Pract 2013

Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
Kwan Il Kim, Kyung Hee Lee, Tae Ryung Kim, Yong Soon Chun, Tae Hoon Lee, Heung Kyu Park. J Breast Cancer 2014

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.